$9.76
−5.20%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.39
From 52W high−26.40%
Volume63665.00
Market cap$1.86B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.39
From 52W high
−26.40%
Volume
63665.00
Market cap
$1.86B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.8x
P/E (TTM)
—
RSI (14)
35.1
MomentumView details →
1D Return
−5.20%
YTD Return
+916.07%
SummaryUpdated Jun 1, 2026
Revolution Medicines, Inc. (NASDAQ:RVMD) is a clinical-stage precision oncology company founded in 2014 and headquartered in Redwood City, California. The company focuses on developing novel targeted therapies specifically designed to treat RAS-addicted cancers, a historically challenging area in oncology that represents a significant unmet medical need. Since its inception, Revolution Medicines has built a comprehensive pipeline of investigational drugs targeting various RAS mutations, positioning itself as a specialized player in the precision oncology space.
Similar companies
Latest newsMore news →
The U.S. FDA granted Breakthrough Therapy Designation to Revolution Medicines' RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel for treatment-naïve metastatic pancreatic adenocarcinoma.6d agoThe FDA approved a pill from Revolution Medicines to treat late-stage prostate cancer.15d agoRevolution Medicines announced that The New England Journal of Medicine published Phase 1/2 clinical data on its drug RASONQUE (daraxonrasib) for metastatic non-small cell lung cancer.18d ago